首页> 美国卫生研究院文献>Diabetology international >Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

【2h】

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

机译：Linagliptin和亚洲人的心肺成果患有2型糖尿病和成立的心血管和/或肾病：随机Carmelina®试验的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version of this article (10.1007/s13340-019-00412-x) contains supplementary material, which is available to authorized users.

机译：本文的在线版本（10.1007 / s13340-019-00412-x）包含补充材料，可供授权用户使用。

著录项

期刊名称 Diabetology international
作者
Nobuya Inagaki; Wenying Yang; Hirotaka Watada; Linong Ji; Sven Schnaidt; Egon Pfarr; Tomoo Okamura; Odd Erik Johansen; Jyothis T. George; Maximilian von Eynatten; Julio Rosenstock; Vlado Perkovic; Christoph Wanner; Mark E. Cooper; John H. Alexander; Issei Komuro; Masaomi Nangaku;
展开▼
作者单位

展开▼
年(卷),期 2020(11),2
年度 2020
页码 129–141
总页数 13
原文格式 PDF
正文语种
中图分类
关键词

机译：糖尿病;2型;心血管疾病;肾功能不全;慢性;处方药;

相似文献

外文文献
中文文献
专利

1. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial [J] . Diabetes care . 2020,第8期

机译：Linaglittin对正常和减少肾功能患者心血管和肾脏结果的影响：Carmelina随机试验的二次分析
2. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ? ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk [J] . Julio Rosenstock, Vlado Perkovic, John H. Alexander, Cardiovascular Diabetology . 2018,第1期

机译：LINAgliptin（CARMELINA？）进行心血管安全性和肾脏微血管结果研究的基本原理，设计和基线特征：一项针对2型糖尿病和高心脏肾脏风险患者的随机，双盲，安慰剂对照临床试验
3. Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial [J] . Ronald CW Ma, Stefano Del Prato, Baptist Gallwitz, Journal of diabetes investigation. . 2018,第3期

机译：与初诊利格列汀相比口服利那列汀和二甲双胍降低血糖作为亚洲初诊新发2型糖尿病和高血糖症患者的初始治疗：一项随机临床试验的亚组分析
4. Hierarchy of risk factors for chronic kidney disease in patients with type 2 diabetes mellitus [C] . Bondor Cosmina Ioana, Kacso Ina Maria, Lenghel Alina Ramona, 2012 IEEE 8th International Conference on Intelligent Computer Communication and Processing. . 2012

机译：2型糖尿病患者慢性肾脏病危险因素的层次
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized placebo‐controlled CARMELINA® trial [O] . Mark E. Cooper, Julio Rosenstock, Takashi Kadowaki, -1

机译：利格列汀治疗2型糖尿病和已确定的心血管疾病和/或肾脏疾病的老年人的心血管和肾脏结局：随机安慰剂对照的CARMELINA®试验的预先确定的亚组分析
7. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial [O] . Mark E. Cooper, Julio Rosenstock, Takashi Kadowaki, 2020

机译：患有2型糖尿病和肾脏疾病和/或肾病的老年人Linagliptin治疗的心血管和肾脏结果：随机安慰剂控制的Carmelina®试验的预先精确的亚组分析

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

摘要

著录项

相似文献

相关主题

期刊订阅